Stryker Corporation (NYSE:) Stock Analysis: BTIG Reaffirms Buy Rating with $360.00 Price Target
BTIG reaffirmed its confidence in Stryker Corporation stock, a leading medical technology company, with a Buy rating and a price target of $360.00. Analysts visited the company's headquarters, meeting key leaders and exploring product offerings.
Key highlights include Stryker's robust organic growth, recent mergers and acquisitions, and potential for growth in advanced technology. The company also reported a 9% organic sales growth and a 10.6% increase in adjusted earnings per share in the second quarter of 2024.
InvestingPro Insights: Stryker's solid track record, market cap of $131.59 billion, and consistent dividend increases make it an attractive investment. The company's position in the Healthcare Equipment & Supplies industry and strategic investments in advanced technology further support its growth potential.
In conclusion, Stryker Corporation's positive outlook, strong financial performance, and focus on innovation make it a compelling investment opportunity for investors looking to capitalize on the healthcare industry's growth.